Mustang Bio

MBIO

Mustang Bio (NASDAQ: MBIO) is a clinical-stage biopharmaceutical company founded in 2015 and headquartered in Worcester, MA, U.S. Operating as a partner company of Fortress Biotech, Mustang Bio develops CAR-T immunotherapies and gene therapies for multiple diseases, including hematologic cancers, solid tumors, and X-linked severe combined immunodeficiency (X-SCID).

Mustang Bio has been a target of short sellers for a while. The current short interest of 0.82% is roughly at the average of the last 12 months (1.20%).